---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-269535"
form_type: "8-K"
ticker: "RCEL"
cik: "0001762303"
company_name: "AVITA Medical, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:52:25.470548+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AVITA Medical Q3 revenue falls 13% YoY to $17.1M; lowers FY2025 revenue guidance to $70-74M

## Summary
- Net loss improved to $13.2M ($0.46 loss per share) from $16.2M in Q3 2024; cash use cut to $6.2M.
- Full-year 2025 revenue guidance lowered to $70-74M from prior $76-81M, citing MAC reimbursement headwinds.
- Sixth amendment to OrbiMed credit agreement adds $500K to principal, resets Q4 2025 revenue covenant to $70M.
- RECELL GO received CE Mark under EU MDR; launch to begin in Germany, Italy, and UK.
- Operating expenses down 24% YoY to $23.0M as part of cost discipline; cash $23.3M at Sept 30.

## SEC filing metadata
- accession: 0001193125-25-269535
- form_type: 8-K
- ticker: RCEL
- cik: 0001762303
- company_name: AVITA Medical, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1762303/000119312525269535/0001193125-25-269535-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1762303/000119312525269535/rcel-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-269535
- JSON: https://secwatch.observer/filing/0001193125-25-269535.json
- Plain text: https://secwatch.observer/filing/0001193125-25-269535.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.